[{"address1": "55 Cambridge Parkway", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 299 8380", "fax": "617 299 8379", "website": "https://www.sagerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.", "fullTimeEmployees": 353, "companyOfficers": [{"maxAge": 1, "name": "Mr. Barry E. Greene", "age": 61, "title": "President, CEO & Director", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1278962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Benecchi", "age": 52, "title": "COO & Treasurer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 757800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory  Shiferman", "title": "Senior VP, General Counsel & Secretary", "fiscalYear": 2024, "totalPay": 617345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Quirk Ph.D.", "title": "Chief Scientific Officer & Interim Head of R&D", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ashley  Kaplowitz", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela  Herbster", "title": "Senior VP and Chief People & Experience Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen  Colquhoun", "title": "Senior Vice President of Drug Safety & Pharmacovigilance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Aaron  Koenig M.D.", "title": "Medical Director of Early Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Helen  Rubinstein", "title": "Investor Relations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 4, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.68, "open": 8.74, "dayLow": 8.68, "dayHigh": 8.68, "regularMarketPreviousClose": 8.68, "regularMarketOpen": 8.74, "regularMarketDayLow": 8.68, "regularMarketDayHigh": 8.68, "payoutRatio": 0.0, "beta": 0.296, "forwardPE": -2.0815349, "volume": 17394354, "regularMarketVolume": 17394354, "averageVolume": 2451528, "averageVolume10days": 5726005, "averageDailyVolume10Day": 5726005, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 544942592, "fiftyTwoWeekLow": 4.62, "fiftyTwoWeekHigh": 9.36, "priceToSalesTrailing12Months": 7.7394524, "fiftyDayAverage": 8.2892, "twoHundredDayAverage": 7.13265, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 190817568, "profitMargins": 0.0, "floatShares": 51314943, "sharesOutstanding": 62781400, "sharesShort": 2215287, "sharesShortPriorMonth": 5252521, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0354, "heldPercentInsiders": 0.10362001, "heldPercentInstitutions": 0.83595, "shortRatio": 0.65, "shortPercentOfFloat": 0.0394, "impliedSharesOutstanding": 62781400, "bookValue": 5.888, "priceToBook": 1.4741849, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -301195008, "trailingEps": -4.89, "forwardEps": -4.17, "enterpriseToRevenue": 2.71, "enterpriseToEbitda": -0.632, "52WeekChange": -0.03125, "SandP52WeekChange": 0.20277917, "quoteType": "EQUITY", "currentPrice": 8.68, "targetHighPrice": 12.0, "targetLowPrice": 6.0, "targetMeanPrice": 8.58333, "targetMedianPrice": 8.5, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 6, "totalCash": 365572000, "totalCashPerShare": 5.823, "ebitda": -302084000, "totalDebt": 11421000, "quickRatio": 8.784, "currentRatio": 9.164, "totalRevenue": 70411000, "debtToEquity": 3.097, "revenuePerShare": 1.141, "returnOnAssets": -0.33780998, "returnOnEquity": -0.60432, "grossProfits": -75231000, "freeCashflow": -177641504, "operatingCashflow": -289343008, "revenueGrowth": 2.658, "grossMargins": -1.06846, "ebitdaMargins": 0.0, "operatingMargins": -1.7119099, "financialCurrency": "USD", "symbol": "SAGE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1405690200000, "regularMarketChange": 0.0, "regularMarketDayRange": "8.68 - 8.68", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2451528, "fiftyTwoWeekLowChange": 4.0600004, "fiftyTwoWeekLowChangePercent": 0.878788, "fiftyTwoWeekRange": "4.62 - 9.36", "fiftyTwoWeekHighChange": -0.67999935, "fiftyTwoWeekHighChangePercent": -0.07264951, "fiftyTwoWeekChangePercent": -3.125, "earningsTimestampStart": 1761681600, "earningsTimestampEnd": 1761681600, "earningsCallTimestampStart": 1745958600, "earningsCallTimestampEnd": 1745958600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.89, "epsForward": -4.17, "epsCurrentYear": -3.61, "shortName": "Sage Therapeutics, Inc.", "longName": "Sage Therapeutics, Inc.", "corporateActions": [{"header": "Delisting", "message": "SAGE is delisted effective Aug. 1, 2025", "meta": {"eventType": "DELISTING", "dateEpochMs": 1754020800000}}], "regularMarketTime": 1753905600, "exchange": "NGM", "messageBoardId": "finmb_141821364", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "priceEpsCurrentYear": -2.4044323, "fiftyDayAverageChange": 0.39080048, "fiftyDayAverageChangePercent": 0.047145743, "twoHundredDayAverageChange": 1.5473504, "twoHundredDayAverageChangePercent": 0.21693906, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 8.68, "marketState": "CLOSED", "displayName": "Sage Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-02"}]